Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Serologicals Corp. (NasdaqNM:SERO)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials
Location
5655 Spalding Drive
Norcross, GA 30092
Phone: (678) 728-2000
Fax: (678) 728-2299
Email: webmaster@serologicals.com
Employees (last reported count): 542
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 39%
·Over the last 6 months:
 · one insider buy; 4,000  shares
 · 2 insider sells; 88.0K shares
  (0.9% of insider shares)
·Institutional: 79% (130% of float)
(152 institutions)
·Net Inst. Buying: 1.37M shares (+6.77%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Serologicals Corporation is a worldwide provider of biological products to life science companies. The Company's products are used in the further development of diagnostic, vaccine and therapeutic products. The Company provides value-added, antibody-based products that are used as the active ingredients in therapeutic products for the treatment and management of diseases such as Rh incompatibility in newborns, rabies and hepatitis and in diagnostic products such as blood typing reagents and diagnostic test kits. Through its protein fractionation facility, Serologicals Corporation provides a variety of proteins used in the manufacturing of diagnostic reagents and tissue culture media components for use as additives in biotech products.
More from Market Guide: Expanded Business Description

Financial Summary
Serologicals Corp. is a worldwide provider of biological products to life science companies. The Company's products are used in the further development of diagnostic, vaccine and therapeutic products. For the six months ended 7/1/01, revenues fell 31% to $53.6 million. Net income totaled $9.2 million, up from $4.4 million. Revenues reflect the abences of sales from Seramed. Net income reflects a lower special charge ($163 thousand, down from $1.8 million).
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Desmond O'Connell, Jr., 65
Chairman
$207K--  
David Dodd, 51
Pres, CEO, Director
204K--  
Peter Pizzo III, 34
CFO, VP-Fin., Sec., Treasurer
248K$103K
Toby Simon, M.D., 56
VP, Medical and Scientific Affairs
198K22K
Sue Sutton-Jones, 48
VP, Worldwide Regulatory Affairs, Quality Assurance and Compliance
--  --  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:SEROAs of 31-Aug-2001
Price and Volume
52-Week Low
on 18-Oct-2000
$5.75 
Recent Price$19.05 
52-Week High
on 4-June-2001
$25.75 
Beta0.64 
Daily Volume (3-month avg)273.2K
Daily Volume (10-day avg)206.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change+140.0%
52-Week Change
relative to S&P500
+222.0%
Share-Related Items
Market Capitalization$456.9M
Shares Outstanding24.0M
Float14.6M
Dividends & Splits
Annual Dividendnone 
Last Split: 3 for 2 on 17-Aug-1998
Per-Share Data
Book Value (mrq*)$5.84 
Earnings (ttm)$0.75 
Earnings (mrq)$0.20 
Sales (ttm)$5.21 
Cash (mrq*)$1.63 
Valuation Ratios
Price/Book (mrq*)3.26 
Price/Earnings (ttm)25.37 
Price/Sales (ttm)3.65 
Income Statements
Sales (ttm)$123.2M
EBITDA (ttm*)$34.8M
Income available to common (ttm)$17.7M
Profitability
Profit Margin (ttm)14.4%
Operating Margin (ttm)23.3%
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter
(fully updated)
1-July-2001
Most recent quarter
(flash earnings)
30-June-2001
Management Effectiveness
Return on Assets (ttm)12.82%
Return on Equity (ttm)14.62%
Financial Strength
Current Ratio (mrq*)10.49 
Debt/Equity (mrq*)0 
Total Cash (mrq)$39.1M
Short Interest
As of 8-Aug-2001
Shares Short336.0K
Percent of Float2.3%
Shares Short
(Prior Month)
597.0K
Short Ratio1.14 
Daily Volume296.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001, except mrq*/ttm* items as of 1-July-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.